ESMO 2019: Advances in Treating Ovarian Cancer, Lung Cancer, and TRK Protein Mutations

Ricardo Cubedo, MD
November 14, 2019
Greg Guthrie, ASCO staff

The 2019 Congress of the European Society for Medical Oncology (ESMO) was held from September 27 to October 1 in Barcelona, Spain. In this podcast, Ricardo Cubedo, MD, discusses 3 highlights from the conferenceshare on twitter and how they may impact patients' lives.

  • Results of the PAOLA-1 study, which examined using a targeted therapy called olaparib (Lynparza) to prevent ovarian cancer from coming back. [2:32]

  • Research from the CheckMate 227 clinical trial looked at whether a combination of immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), was more effective at stopping non-small cell lung cancer (NSCLC) than chemotherapy, which is the standard treatment. [6:08]

  • Data from 2 basket trials (named SCOUT and NAVIGATE) were presented, showing the effectiveness of tumor-agnostic treatment using the targeted therapy drug larotrectinib (Vitrakvi) that targets the TRK protein in a group of patients with many different types of cancer. [10:45]

Dr. Cubedo is the Head of Sarcomas and Hereditary Cancer with the Medical Oncology Service at MD Anderson Cancer Center Madrid in Spain. He is also a member of the Cancer.Net Editorial Board.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.